Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05167409 | A Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer | PHASE2 | ACTIVE NOT_RECRUITING | 48 | — | — | Jul 28, 2022 | Mar 1, 2026 | Jan 13, 2025 | 4 | United States |
To determine the recommended dose (RD) of evorpacept (ALX148) in combination with cetuximab and pembrolizumab
To determine the objective response rate (ORR), defined as partial response or complete response, with evorpacept (ALX148), cetuximab, and pembrolizumab using RECIST v1.1 in patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC) who have progressed on at least two lines of standard therapy
| Arm | Type | Description |
|---|---|---|
| Evorpacept (ALX148) + cetuximab + pembrolizumab | EXPERIMENTAL | Evorpacept (ALX148) + cetuximab + pembrolizumab. Evorpacept (ALX148) 15 mg/kg IV weekly, cetuximab 400 mg/m2 once then 250 mg/m2 weekly, and pembrolizumab 200 mg every 3 weeks |
| Name | Type | Description |
|---|---|---|
| Evorpacept (ALX148) | DRUG | IV QW |
| Cetuximab | DRUG | IV QW |
| Pembrolizumab | DRUG | IV Q3W |
Inclusion Criteria: To be eligible to participate in this study, an individual must meet all of the following criteria: * Have a diagnosis of metastatic colorectal cancer previously treated with at least two lines of therapy for unresectable/metastatic disease * Have microsatellite stable disease ...